GAITHERSBURG, Md., May 05, 2022 (World NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a scientific-phase biopharmaceutical firm, now declared that it will report its initial quarter 2022 economical effects on Thursday, May well 12, 2022 and will supply a company update.
Altimmune administration will host a convention get in touch with at 8:30 am E.T. on Might 12 to focus on financial benefits and provide a business enterprise update.
Meeting Call Data:
Altimmune is a medical-stage biopharmaceutical corporation centered on the growth of novel peptide-based therapeutics for the remedy of weight problems and liver illnesses. The company’s lead solution candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is currently being created for the treatment of weight problems and NASH. In addition, Altimmune is producing HepTcell™, an immunotherapeutic created to reach a useful overcome for chronic hepatitis B. For additional information, you should go to www.altimmune.com.
Stick to @Altimmune, Inc. on LinkedIn
Abide by @AltimmuneInc on Twitter
Investor and Media Contact:
Main Economic Officer